CONNECT WITH US
HealthTech

HealthTech

FDA charts path for approval of individualized gene editing therapies

Endpoints News logo

Published on

Add as a preferred source on Google
FDA charts path for approval of individualized gene editing therapies

The FDA has out­lined steps drug­mak­ers can take to seek reg­u­la­to­ry ap­proval for gene edit­ing med­i­cines tai­lored to fix a sin­gle per­son’s dis­ease-caus­ing mu­ta­tion. The …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Den­mark's Gubra looks be­yond me­tab­o­lism, hopes for first port­fo­lio com­pa­ny this year October 27, 2026

Arti­va to wind down af­ter two pa­tient deaths in au­toim­mune cell ther­a­py tri­als October 27, 2026

An­throp­ic's lat­est biotech buy is a one-man stealth start­up run by a pseu­do­ny­mous Twit­ter poster

Cit­ing 'safe­ty' and 'free­dom,' HHS will al­low com­pound­ing of cer­tain well­ness pep­tides

Backed by Amish and Men­non­ites, a new kind of gene ther­a­py com­pa­ny takes shape

Now 78% of sci­en­tists say AI will speed drug dis­cov­ery this year: Sig­nal Sur­vey



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.